首页 > 心血管医学词汇大全 > drug-eluting stent
Evaluation of the incremental prognostic value of the combination of CYP2C19 poor metabolizer status and ABCB1 3435 TT polymorphism over conventional risk factors for cardiovascular events after drug-eluting stent implantation in East Asians
评估 CYP2C19 代谢不良状态和 ABCB1 3435 TT 多态性对东亚人药物洗脱支架植入术后心血管事件传统危险因素的增量预后价值
ABCB1 3435 TT polymorphism clopidogrel CYP2C19 poor metabolizer genotyping reclassification
下载

摘要

Genet Med 18 8, 833–841. Purpose: We evaluated the incremental prognostic value of combining the CYP2C19 poor metabolizer (PM) and ABCB1 3435 TT for adverse clinical outcomes over conventional risk factors in a percutaneous coronary intervention (PCI) cohort. Methods: We enrolled 2,188 patients. The primary end point was a composite of death from any cause, nonfatal myocardial infarction (MI), and stroke during 1-year follow-up. The population was stratified into the following four groups: CYP2C19 EM/IM+ ABCB1 3435 CC/CT, CYP2C19 EM/IM+ ABCB1 3435 TT, CYP2C19 PM+ ABCB1 3435 CC/CT, and CYP2C19 PM+ ABCB1 3435 TT. Results: A total of 87 (3.97%) primary end-point events occurred (64 deaths, 8 non-fatal MIs and 15 strokes). Multivariate Cox analysis indicated that CYP2C19 PM+ ABCB1 3435 TT status was a significant predictor of the primary end point (hazard ratio = 4.51, 95% confidence interval (CI) = 1.92–10.58). However, addition of combined genetic status to the clinical risk model did not improve the model discrimination (C-statistic = 0.786 (95% CI = 0.734–0.837) to 0.785 (95% CI = 0.733–0.838)) or risk reclassification (categorical net reclassification improvement (0.040, P = 0.32), integrated discrimination improvement (0.021, P = 0.026)). Conclusions: In a real-world East Asian PCI population taking clopidogrel, although the concurrent presence of CYP2C19 PM and ABCB1 TT is a strong independent predictor of adverse outcomes, the combined status of two at-risk variants does not have an incremental prognostic value beyond that of the conventional clinical risk factors.

译文

Genet Med 18 8,833-841。目的: 我们评估了在经皮冠状动脉介入治疗 (PCI) 队列中,结合 CYP2C19 低代谢 (PM) 和 ABCB1 3435 TT 对传统危险因素的不良临床结果的增量预后价值。方法: 我们招募了 2,188 名患者。主要终点是任何原因导致的死亡、非致死性心肌梗死 (MI) 和 1 年随访期间的中风的复合。人群被分为以下四组: CYP2C19 EM/IM ABCB1 3435 CC/CT,CYP2C19 EM/IM ABCB1 3435 TT,CYP2C19 PM ABCB1 3435 CC/CT, 和 CYP2C19 PM ABCB1 3435 TT。结果: 共发生 87 例 (3.97%) 主要终点事件 (64 例死亡,8 例非致命 MIs 和 15 例中风)。多变量 Cox 分析表明 CYP2C19 PM ABCB1 3435 TT 状态是主要终点的重要预测因子 (风险比 = 4.51,95% 置信区间 (CI) = 1.92-10.58)。然而,在临床风险模型中添加联合遗传状态并没有提高模型的区分度 (C-统计量 = 0.786 (95% CI = 0.734-0.837) 至 0.785 (95% CI = 0.733-0.838)) 或风险重新分类 (分类净重新分类改善 (0.040,P = 0.32),综合区别改善 (0.021,P = 0.026))。结论: 在现实世界中,东亚人群服用氯吡格雷,尽管 CYP2C19 PM 和 ABCB1 TT 的同时存在是不良后果的强独立预测因子, 两种高危变异的联合状态除了常规临床风险因素外,没有增加预后价值。

drug-eluting stent

心血管 药物支架 治疗仪器
概述  :  

药物洗脱支架(DES)由3部分构成:①金属支架骨架本身;②具有降低新生内膜过度增殖或其他抑制作用的药物;③保持有效药物浓度、延缓(控制)药物释放、阻断过度增生生物学过程的高分子聚合物。药物洗脱支架以支架为载体,靶向性地携带药物到达血管损伤局部,并且药物一定时间内持续作用于支架置入部位,抑制血管壁的炎性反应和内膜的过度增生,降低介入治疗术后再狭窄。药物洗脱支架的应用在介入心脏病学里是一次重要的革新。药物洗脱支架的有效应用极大地减少了再狭窄和再次介入手术的发生率。理想DES应具备的特征(1)具有

Drug 英 [drʌg]  美 [drʌg] 

       n. 药;毒品;麻醉药;滞销货

vt. 使服麻醉药;使服毒品;掺麻醉药于

vi. 吸毒

      drug therapy 药物治疗;药物疗法

drug abuse 药物滥用;毒品滥用

同根词   n. druggist 药剂师;药商;

       Have you a concern than any drug that.

有你的一句关心比任何药物都好使。

 

eluting

       v. (化)洗提(elute 的现在分词)

      eluting order 洗脱顺序

eluting gas 流出气体

eluting solvent 冲洗溶剂

       The prevention of in stent restenosis includes drug-eluting stent, drug therapy and 

gene therapy.

安放支架后再狭窄的预防包括安放药物洗脱支架、药物治疗和基因治疗。

 

 

Stent [stent] 

       n. 斯滕特氏印模膏;展伸  adj. 扩张的

      Metal stent 金属支架;内支架;固定人工瓣膜的架子

stent restenosis 支架内再狭窄;预防和治疗支架再狭窄

       But physicians should be concerned that we've not solved the problem of late stent thrombosis. 

但是内科医生应注意的是,我们还没有解决晚期支架血栓形成问题。


请扫描右侧二维码,免费查看词汇专业知识背景